{"doi":"10.1093/ndt/gfad175","title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","abstract":"<jats:title>ABSTRACT</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin–angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8% and –10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin &amp;lt;3.5 g/dL, 0.53; 95% CI 0.30–0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: –3.7 versus –5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.</jats:p>\n               </jats:sec>","journal":"Nephrology Dialysis Transplantation","year":2024,"id":599872,"datarank":0.5742962094733643,"base_score":3.828641396489095,"endowment":3.828641396489095,"self_citation_contribution":0.5742962094733643,"citation_network_contribution":0.0,"self_endowment_contribution":0.5742962094733643,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":45,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":739333,"name":"Kate Stevens","orcid":"0000-0003-2291-1692","position":1,"is_corresponding":false},{"id":1537519,"name":"Maite Padrón","orcid":null,"position":2,"is_corresponding":false},{"id":787717,"name":"Ana Huerta","orcid":"0000-0003-3342-7628","position":3,"is_corresponding":false},{"id":1537520,"name":"Marco Montomoli","orcid":"0000-0003-1412-6352","position":4,"is_corresponding":false},{"id":1537521,"name":"Juan Villa","orcid":null,"position":5,"is_corresponding":false},{"id":1537522,"name":"Fayna González","orcid":null,"position":6,"is_corresponding":false},{"id":1537523,"name":"Cristina Vega","orcid":null,"position":7,"is_corresponding":false},{"id":1537524,"name":"Manuel López Mendoza","orcid":null,"position":8,"is_corresponding":false},{"id":1537525,"name":"Loreto Fernández","orcid":null,"position":9,"is_corresponding":false},{"id":1537526,"name":"Amir Shabaka","orcid":"0000-0001-7039-4701","position":10,"is_corresponding":false},{"id":1537527,"name":"Antolina Rodríguez-Moreno","orcid":null,"position":11,"is_corresponding":false},{"id":1537528,"name":"Adoración Martín-Gómez","orcid":null,"position":12,"is_corresponding":false},{"id":1537529,"name":"Pedro J Labrador","orcid":null,"position":13,"is_corresponding":false},{"id":1537531,"name":"Alicia Molina Andújar","orcid":null,"position":14,"is_corresponding":false},{"id":1537534,"name":"M Carmen Prados Soler","orcid":null,"position":15,"is_corresponding":false},{"id":1537536,"name":"Luis Martín-Penagos","orcid":null,"position":16,"is_corresponding":false},{"id":1537538,"name":"Estefanía Yerovi","orcid":null,"position":17,"is_corresponding":false},{"id":1537540,"name":"Laura Medina Zahonero","orcid":null,"position":18,"is_corresponding":false},{"id":1537542,"name":"José Carlos De La Flor","orcid":null,"position":19,"is_corresponding":false},{"id":1537544,"name":"Carmen Mon","orcid":null,"position":20,"is_corresponding":false},{"id":1537546,"name":"Meritxell Ibernon","orcid":null,"position":21,"is_corresponding":false},{"id":1537549,"name":"Astrid Rodríguez Gómez","orcid":null,"position":22,"is_corresponding":false},{"id":1250191,"name":"Rosa Miquel","orcid":"0000-0001-7414-0186","position":23,"is_corresponding":false},{"id":1537554,"name":"Milagros Sierra","orcid":null,"position":24,"is_corresponding":false},{"id":1537556,"name":"Victoria Mascarós","orcid":null,"position":25,"is_corresponding":false},{"id":1537558,"name":"Leonella Luzardo","orcid":null,"position":26,"is_corresponding":false},{"id":1537559,"name":"Marios Papasotiriou","orcid":"0000-0001-9375-989X","position":27,"is_corresponding":false},{"id":1016635,"name":"David Arroyo","orcid":"0000-0003-4652-0311","position":28,"is_corresponding":false},{"id":1017484,"name":"Úrsula Verdalles","orcid":null,"position":29,"is_corresponding":false},{"id":1537562,"name":"Patricia Martínez-Miguel","orcid":null,"position":30,"is_corresponding":false},{"id":1537563,"name":"Gonzalo Ramírez-Guerrero","orcid":null,"position":31,"is_corresponding":false},{"id":1537564,"name":"Saúl Pampa-Saico","orcid":"0000-0001-7811-1737","position":32,"is_corresponding":false},{"id":904843,"name":"Esperanza Moral Berrio","orcid":"0000-0002-3690-6598","position":33,"is_corresponding":false},{"id":1537565,"name":"José Luis Pérez Canga","orcid":"0000-0001-6753-1146","position":34,"is_corresponding":false},{"id":1537566,"name":"Blanca Tarragón","orcid":"0000-0003-1784-6929","position":35,"is_corresponding":false},{"id":1537567,"name":"Pilar Fraile Gómez","orcid":null,"position":36,"is_corresponding":false},{"id":1537568,"name":"Dabaiba Regidor","orcid":null,"position":37,"is_corresponding":false},{"id":1537569,"name":"Javier Relea","orcid":null,"position":38,"is_corresponding":false},{"id":1537570,"name":"Marc Xipell","orcid":null,"position":39,"is_corresponding":false},{"id":1537572,"name":"Cristina Andrades Gómez","orcid":null,"position":40,"is_corresponding":false},{"id":1537574,"name":"Maruja Navarro","orcid":null,"position":41,"is_corresponding":false},{"id":1537575,"name":"Álvaro Álvarez","orcid":null,"position":42,"is_corresponding":false},{"id":1537576,"name":"Begoña Rivas","orcid":null,"position":43,"is_corresponding":false},{"id":731464,"name":"Luís F. Quintana","orcid":"0000-0001-7582-8476","position":44,"is_corresponding":false},{"id":336794,"name":"Eduardo Gutiérrez","orcid":"0000-0002-8533-5680","position":45,"is_corresponding":false},{"id":1537577,"name":"Miguel Ángel Pérez-Valdivia","orcid":null,"position":46,"is_corresponding":false},{"id":1224106,"name":"Balazs Odler","orcid":"0000-0002-8176-5202","position":47,"is_corresponding":false},{"id":284191,"name":"Andreas Kronbichler","orcid":"0000-0002-2945-2946","position":48,"is_corresponding":false},{"id":336791,"name":"Colin Geddes","orcid":"0000-0001-6747-6423","position":49,"is_corresponding":false},{"id":1537578,"name":"Hans-Joachim Anders","orcid":null,"position":50,"is_corresponding":false},{"id":284160,"name":"Jürgen Floege","orcid":"0000-0002-8763-828X","position":51,"is_corresponding":false},{"id":1537579,"name":"Gema Fernández-Juárez","orcid":null,"position":52,"is_corresponding":false},{"id":90338,"name":"Manuel Praga","orcid":"0000-0001-9270-1071","position":53,"is_corresponding":false},{"id":1016627,"name":"Fernando Caravaca‐Fontán","orcid":"0000-0002-5830-9663","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","abstract":"<jats:title>ABSTRACT</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin–angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8% and –10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin &amp;lt;3.5 g/dL, 0.53; 95% CI 0.30–0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: –3.7 versus –5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.</jats:p>\n               </jats:sec>","is_dataset_classified":null,"base_score":3.828641396489095,"endowment":3.828641396489095,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37550217","pmcid":null,"openalex_id":"https://openalex.org/W4385647401","authors":[],"funders":[{"funder_name":"Fernando Caravaca-Fontán","grant_id":"JR21/00018","title":null},{"funder_name":"FWF","grant_id":"J4664-B","title":null},{"funder_name":"Department of Medicine","grant_id":"","title":null},{"funder_name":"University of Cambridge","grant_id":"","title":null},{"funder_name":"Spanish Young Nephrologists Platform","grant_id":"","title":null},{"funder_name":"Spanish Young Nephrologists Platform","grant_id":"","title":null},{"funder_name":"University of Cambridge","grant_id":"","title":null},{"funder_name":"Department of Medicine","grant_id":"","title":null}],"total_grants":8,"fwci":6.8161,"citation_percentile":0.97848245,"influential_citations":0,"citation_trend":[{"year":2023,"count":2},{"year":2024,"count":11},{"year":2025,"count":24},{"year":2026,"count":8}],"oa_status":"bronze","license":"https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model","oa_locations":[{"url":"https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfad175/51283027/gfad175.pdf","host_type":"journal"},{"url":"https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfad175/51283027/gfad175.pdf","host_type":"publisher"},{"url":"https://academic.oup.com/ndt/article-pdf/39/2/328/56437483/gfad175.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ndt/gfad175","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37550217","host_type":"repository"}],"fields_of_study":["Renal Diseases and Glomerulopathies","Vasculitis and related conditions","Diabetes Treatment and Management","Adult","Humans","Middle Aged","Cohort Studies","Kidney Diseases","Glomerulonephritis","Proteinuria","Serum Albumin","Sodium","Glucose","Diabetes Mellitus, Type 2"],"mesh_terms":["Adult","Diabetes Mellitus, Type 2","Glomerulonephritis","Glucose","Humans","Kidney Diseases","Middle Aged","Proteinuria","Serum Albumin","Sodium","Cohort Studies"],"keywords":["Medicine","Proteinuria","Internal medicine","Renal function","Retrospective cohort study","Albuminuria","Odds ratio","Kidney disease","Gastroenterology","Endocrinology","Urology","Kidney","body mass index","Glomerular Disease","Estimated Glomerular Filtration Rate","Sodium-glucose Cotransporter 2 Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T11:31:16.614523Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}